In Vivo Relevance of a Biphasic In Vitro Dissolution Test for the Immediate Release Tablet Formulations of Lamotrigine

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Oct 28

PMID 37896234

Authors

Tuba Incecayir

Muhammed Enes Demir

Affiliations

Soon will be listed here.

Abstract

Biphasic in vitro dissolution testing is an attractive approach to reflect on the interplay between drug dissolution and absorption for predicting the bioperformance of drug products. The purpose of this study was to investigate the in vivo relevance of a biphasic dissolution test for the immediate release (IR) formulations of a Biopharmaceutics Classification System (BCS) Class II drug, lamotrigine (LTG). The biphasic dissolution test was performed using USP apparatus II with the dual paddle modification. A level A in vitro-in vivo correlation (IVIVC) was constructed between the in vitro partition into the octanol and absorption data of the reference product. A good relation between in vitro data and absorption was obtained (r = 0.881). The one-compartment open model was introduced to predict the human plasma profiles of the test product. The generic product was found to be bioequivalent to the original product in terms of 80-125% bioequivalence (BE) criteria (85.9-107% for the area under the plasma concentration curve () and 82.7-97.6% for the peak plasma concentration () with a 90% confidence interval (CI)). Overall, it was revealed that the biphasic dissolution test offers a promising ability to estimate the in vivo performance of IR formulations of LTG, providing considerable time and cost savings in the development of generic drug products.

Citing Articles

In vitro comparative quality evaluation of different brands of Amlodipine Tablets Commercially available in Jimma Town, South-western Ethiopia.

Milkesa A, Hasen G, Mohammed T, Mekasha Y, Dedefo D, Umeta B PLoS One. 2024; 19(11):e0310828.

PMID: 39561126 PMC: 11575810. DOI: 10.1371/journal.pone.0310828.

References

Heigoldt U, Sommer F, Daniels R, Wagner K . Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test. Eur J Pharm Biopharm. 2010; 76(1):105-11. DOI: 10.1016/j.ejpb.2010.05.006. View

ODwyer P, Box K, Imanidis G, Vertzoni M, Reppas C . On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state. Eur J Pharm Sci. 2021; 168:106034. PMC: 8665220. DOI: 10.1016/j.ejps.2021.106034. View

NIEBERGALL P, Patil M, Sugita E . Simultaneous determination of dissolution and partitioning rates in vitro. J Pharm Sci. 1967; 56(8):943-7. DOI: 10.1002/jps.2600560803. View

Fitton A, Goa K . Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs. 1995; 50(4):691-713. DOI: 10.2165/00003495-199550040-00008. View

Rambeck B, Wolf P . Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet. 1993; 25(6):433-43. DOI: 10.2165/00003088-199325060-00003. View

Incecayir T, Agabeyoglu I, Gucuyener K . Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers. Arzneimittelforschung. 2007; 57(8):517-21. DOI: 10.1055/s-0031-1296641. View

Pestieau A, Krier F, Lebrun P, Brouwers A, Streel B, Evrard B . Optimization of a PGSS (particles from gas saturated solutions) process for a fenofibrate lipid-based solid dispersion formulation. Int J Pharm. 2015; 485(1-2):295-305. DOI: 10.1016/j.ijpharm.2015.03.027. View

Hoa N, Kinget R . Design and evaluation of two-phase partition-dissolution method and its use in evaluating artemisinin tablets. J Pharm Sci. 1996; 85(10):1060-3. DOI: 10.1021/js960115u. View

Cohen A, Land G, Breimer D, Yuen W, Winton C, Peck A . Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 1987; 42(5):535-41. DOI: 10.1038/clpt.1987.193. View

10.

Dressman J, Amidon G, Reppas C, Shah V . Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998; 15(1):11-22. DOI: 10.1023/a:1011984216775. View

11.

Lehto P, Kortejarvi H, Liimatainen A, Ojala K, Kangas H, Hirvonen J . Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs. Eur J Pharm Biopharm. 2011; 78(3):531-8. DOI: 10.1016/j.ejpb.2011.02.007. View

12.

Wagner J . Estimation of theophylline absorption rate by means of the Wagner-Nelson equation. J Allergy Clin Immunol. 1986; 78(4 Pt 2):681-8. DOI: 10.1016/0091-6749(86)90046-1. View

13.

Locher K, Borghardt J, Frank K, Kloft C, Wagner K . Evolution of a mini-scale biphasic dissolution model: Impact of model parameters on partitioning of dissolved API and modelling of in vivo-relevant kinetics. Eur J Pharm Biopharm. 2016; 105:166-75. DOI: 10.1016/j.ejpb.2016.06.008. View

14.

Denninger A, Westedt U, Wagner K . Shared IVIVR for Five Commercial Enabling Formulations Using the BiPHa+ Biphasic Dissolution Assay. Pharmaceutics. 2021; 13(2). PMC: 7927064. DOI: 10.3390/pharmaceutics13020285. View

15.

Btaiche I, Woster P . Gabapentin and lamotrigine: novel antiepileptic drugs. Am J Health Syst Pharm. 1995; 52(1):61-9. DOI: 10.1093/ajhp/52.1.61. View

16.

Deng J, Staufenbiel S, Hao S, Wang B, Dashevskiy A, Bodmeier R . Development of a discriminative biphasic in vitro dissolution test and correlation with in vivo pharmacokinetic studies for differently formulated racecadotril granules. J Control Release. 2017; 255:202-209. DOI: 10.1016/j.jconrel.2017.04.034. View

17.

Phillips D, Pygall S, Cooper V, Mann J . Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J Pharm Pharmacol. 2012; 64(11):1549-59. DOI: 10.1111/j.2042-7158.2012.01523.x. View

18.

Rothwell J, Day A, Morgan M . Experimental determination of octanol-water partition coefficients of quercetin and related flavonoids. J Agric Food Chem. 2005; 53(11):4355-60. DOI: 10.1021/jf0483669. View

19.

Xu H, Vela S, Shi Y, Marroum P, Gao P . In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. Mol Pharm. 2017; 14(11):3801-3814. DOI: 10.1021/acs.molpharmaceut.7b00552. View

20.

Al Durdunji A, AlKhatib H, Al-Ghazawi M . Development of a biphasic dissolution test for Deferasirox dispersible tablets and its application in establishing an in vitro-in vivo correlation. Eur J Pharm Biopharm. 2016; 102:9-18. DOI: 10.1016/j.ejpb.2016.02.006. View